- Home
- NUVB vs CSTL Comparison
NUVB vs CSTL Comparison
Compare NUVB & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- CSTL
- Stock Information
- Founded
- NUVB 2018
- CSTL 2007
- Country
- NUVB United States
- CSTL United States
- Employees
- NUVB N/A
- CSTL N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- NUVB Health Care
- CSTL Health Care
- Exchange
- NUVB Nasdaq
- CSTL Nasdaq
- Market Cap
- NUVB 774.1M
- CSTL 848.1M
- IPO Year
- NUVB N/A
- CSTL 2019
- Fundamental
- Price
- NUVB $2.21
- CSTL $25.75
- Analyst Decision
- NUVB Strong Buy
- CSTL Strong Buy
- Analyst Count
- NUVB 6
- CSTL 6
- Target Price
- NUVB $7.67
- CSTL $40.33
- AVG Volume (30 Days)
- NUVB 1.7M
- CSTL 358.8K
- Earning Date
- NUVB 03-03-2025
- CSTL 02-27-2025
- Dividend Yield
- NUVB N/A
- CSTL N/A
- EPS Growth
- NUVB N/A
- CSTL N/A
- EPS
- NUVB N/A
- CSTL 0.21
- Revenue
- NUVB $2,162,000.00
- CSTL $311,878,000.00
- Revenue This Year
- NUVB N/A
- CSTL $51.99
- Revenue Next Year
- NUVB $374.06
- CSTL N/A
- P/E Ratio
- NUVB N/A
- CSTL $122.41
- Revenue Growth
- NUVB N/A
- CSTL 62.43
- 52 Week Low
- NUVB $1.67
- CSTL $16.97
- 52 Week High
- NUVB $4.16
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NUVB 37.58
- CSTL 37.34
- Support Level
- NUVB $2.16
- CSTL $26.65
- Resistance Level
- NUVB $2.38
- CSTL $28.48
- Average True Range (ATR)
- NUVB 0.12
- CSTL 1.12
- MACD
- NUVB 0.00
- CSTL -0.17
- Stochastic Oscillator
- NUVB 16.13
- CSTL 0.94
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.